Skip to main content

Oral Integrin Deal Benchmarks in Gastroenterology

Median Upfront
$693M
Range: $371M - $1.0B
Total Deal Value
$3.5B
Range: $2.2B - $4.8B
Royalty Rate
8.3% - 15.4%
Tiered up to 19.4%
Dev Milestones
$596M
Range: $390M - $806M
Model Your Deal

Market Analysis

Oral Integrin therapies in gastroenterology have seen significant M&A and licensing activity in recent years. Based on analysis of 1,500+ verified transactions, the median upfront payment for a Phase 2 oral integrin asset in gastroenterology is $693M, with total deal values reaching $3.5B. Development milestones average $596M, while regulatory milestones contribute $710M.

The gastroenterology oral integrin landscape is characterized by moderate-to-high competitive intensity concentrated in IBD and eosinophilic GI disorders. TL1A inhibitors, gut-selective integrins, and S1P modulators are broadening the therapeutic toolkit beyond TNF and integrin blockade. The recommended deal structure allocates approximately 20% to upfront payments and 80% to milestones, reflecting the risk-reward profile at the Phase 2 stage.

Royalty rates for oral integrin gastroenterology deals range from 8.3% to 15.4% at the base tier, with tiered escalation reaching 12.3%-19.4% on blockbuster sales. Commercial milestones averaging $1.5B further reward successful market penetration.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

What is the typical upfront for a oral integrin gastroenterology licensing deal?
Based on our analysis, Phase 2 oral integrin licensing deals in gastroenterology average $693M in upfront payments, with a range of $371M to $1.0B depending on data quality, competitive positioning, and territorial scope.
What is the total deal value for oral integrin gastroenterology transactions?
The median total deal value for Phase 2 oral integrin assets in gastroenterology is $3.5B, ranging from $2.2B to $4.8B. This includes development milestones ($596M), regulatory milestones ($710M), and commercial milestones ($1.5B).
What royalty rates are standard for oral integrin deals in gastroenterology?
Base royalty rates for oral integrin gastroenterology transactions range from 8.3% to 15.4%, with tiered escalations reaching 12.3%-19.4% on peak sales. Rates are influenced by mechanism differentiation, competitive landscape, and territorial scope.
How are milestones structured in oral integrin gastroenterology deals?
Oral Integrin gastroenterology deals allocate approximately 80% of total deal value to milestones. Development milestones ($596M) make up the largest share, followed by commercial milestones ($1.5B) and regulatory milestones ($710M).
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Small Molecule in Gastroenterology

View

Monoclonal Antibody in Gastroenterology

View

Oral Integrin in Immunology & Autoimmune

View

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating
For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included